The global viral vector & plasmid DNA manufacturing market size is expected to reach USD 882.9 million by 2025, according to a new report by Grand View Research, Inc., rising at a 16.0% CAGR during the forecast period. Rising number of gene therapy-based discovery programs in the pharma industry is one of the key trends driving the production of gene therapy vectors. Moreover, a robust pipeline of viral vaccines and gene therapies has prompted companies to develop novel and effective technologies for scalable manufacturing of vectors. Current vector manufacturing process is considered highly regulated, elaborate, and expensive.

Moreover, at present, there is a shortage of production sites to meet the demand by the pharmaceutical industry for vector construction services. These factors have created opportunities for companies to capitalize on potential avenues in the market through developing novel solutions.

Key growth strategies adopted by companies to sustain their market presence include continuous expansion of manufacturing sites in high-demand markets such as the U.S. and U.K. Moreover, companies are engaged in strategic mergers & facility acquisitions to meet growing requirements of viral vectors within the pharmaceutical and biotech industries and to broaden their service portfolios.

Further Key Findings From the Report Suggest:

  • Adenovirus and retrovirus were prominent vector type segments in the market in 2017. These can be produced at high titers and induce a strong humoral and, especially, a strong T cell response, as a result of which these vector type is extensively employed in vaccines
  • Lentiviral production costs nearly up to 40.0% of the total cost of goods, thus inducing revenue growth in this vector type
  • Downstream processing accounted for the largest share in 2017, owing to requirement of expensive equipment and skilled personnel for product recovery
  • In terms of application, vector manufacturing for antisense, RNAi, & molecular therapy production represented the leading revenue share in 2017. This is due to high adoption rate of viruses for oligonucleotide and aptamers development in comparison to other applications
  • The number of biotech companies that are engaged in employing vector for therapeutic production continue to increase over the period
  • Recent approval of cancer gene therapy products encourages further efforts in this arena, thus resulting in the cancer segment holding the dominant revenue share
  • North America led the global market owing to presence of several universities and research institutes that are engaged in genomic research programs
  • Cobra Biologics, Merck, uniQure N.V., and Novasep are some key participants that are focusing towards capitalizing of untapped avenues in the market.